Vigil Neuroscience, Inc. (VIGL)

USD 2.75

(7.42%)

Market Cap (In USD)

128.34 Million

Revenue (In USD)

-

Net Income (In USD)

-82.63 Million

Avg. Volume

227.02 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.61-6.06
PE
-1.33
EPS
-2.07
Beta Value
1.934
ISIN
US92673K1088
CUSIP
92673K108
CIK
1827087
Shares
46671535.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
Employee Count
-
Website
https://www.vigilneuro.com
Ipo Date
2022-01-07
Details
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.